BR112014015322A2 - compostos e composições para inibir a interação de bcl2 com parceiros de ligação - Google Patents

compostos e composições para inibir a interação de bcl2 com parceiros de ligação

Info

Publication number
BR112014015322A2
BR112014015322A2 BR112014015322A BR112014015322A BR112014015322A2 BR 112014015322 A2 BR112014015322 A2 BR 112014015322A2 BR 112014015322 A BR112014015322 A BR 112014015322A BR 112014015322 A BR112014015322 A BR 112014015322A BR 112014015322 A2 BR112014015322 A2 BR 112014015322A2
Authority
BR
Brazil
Prior art keywords
compounds
bcl
interaction
formula
compositions
Prior art date
Application number
BR112014015322A
Other languages
English (en)
Other versions
BR112014015322A8 (pt
Inventor
Ford Daniel
Robert Porter John
Scott Visser Michael
Yusuff Naeem
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014015322A8 publication Critical patent/BR112014015322A8/pt
Publication of BR112014015322A2 publication Critical patent/BR112014015322A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

abstract the present invention relates to compounds of formula i: in which r1, r2, r3 and r4 are as defined in the summary of the invention. compounds of formula i are capable of disrupting the bcl-2 interations with proteins containing a bh3 domain. disrupting this interaction can restore the anti-apoptotic function of bcl-2 in cancer cells and tumor tissue expressing bcl-2. the invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancerous diseases. tradução do resumo resumo patente de invenção: "compostos e composições para inibir a interação de bcl2 com parceiros de ligação". a presente invenção refere-se aos compostos da fórmula i: na qual r1, r2, r3 e r4 são conforme definidos no sumário da invenção. os compostos da fórmula i são capazes de interferir nos processos de interação entre bcl-2 e proteínas contendo um domínio bh3. a interferência nesta interação pode restaurar a função apoptótica de bcl-2 em células cancerosas e no tecido tumoral que expressa bcl-2. a invenção provê ainda um processo para o preparo de compostos da invenção, de preparados farmacêuticos que compreendem tais compostos e de métodos para o uso de tais compostos no tratamento de doenças cancerosas.
BR112014015322A 2011-12-23 2012-12-12 compostos e composições para inibir a interação de bcl2 com parceiros de ligação BR112014015322A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161579724P 2011-12-23 2011-12-23
PCT/US2012/069270 WO2013096059A1 (en) 2011-12-23 2012-12-12 Compounds for inhibiting the interaction of bcl2 with binding partners

Publications (2)

Publication Number Publication Date
BR112014015322A8 BR112014015322A8 (pt) 2017-06-13
BR112014015322A2 true BR112014015322A2 (pt) 2017-06-13

Family

ID=47429052

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014015322A BR112014015322A2 (pt) 2011-12-23 2012-12-12 compostos e composições para inibir a interação de bcl2 com parceiros de ligação

Country Status (11)

Country Link
US (1) US9126979B2 (pt)
EP (1) EP2794591A1 (pt)
JP (1) JP2015503518A (pt)
KR (1) KR20140104047A (pt)
CN (1) CN104125954A (pt)
AU (1) AU2012355623A1 (pt)
BR (1) BR112014015322A2 (pt)
CA (1) CA2859869A1 (pt)
EA (1) EA201491264A1 (pt)
MX (1) MX2014007730A (pt)
WO (1) WO2013096059A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126980B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
FR3008976A1 (fr) 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
FR3008978A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
FR3008979B1 (fr) 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
KR20200094734A (ko) 2017-09-22 2020-08-07 주빌런트 에피파드 엘엘씨 Pad 억제제로서의 헤테로사이클릭 화합물
DK3697785T3 (da) 2017-10-18 2023-04-03 Jubilant Epipad LLC Imidazo-pyridine forbindelser som pad-inhibitorer
AU2018362046B2 (en) 2017-11-06 2023-04-13 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
CA3083374A1 (en) 2017-11-24 2019-05-31 Jubilant Episcribe Llc Heterocyclic compounds as prmt5 inhibitors
AU2019234185A1 (en) 2018-03-13 2020-10-01 Jubilant Prodel LLC. Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
EP3788042A4 (en) 2018-04-29 2022-01-26 BeiGene, Ltd. BCL-2 INHIBITORS
CN110746355B (zh) * 2018-07-24 2023-08-11 中国科学院上海有机化学研究所 一种苯基吡唑类化合物、药物组合物、其制备方法及应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (pt) 1992-04-03 1994-06-21 Ciba Geigy Ag
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
DK0817775T3 (da) 1995-03-30 2001-11-19 Pfizer Quinazolinderivater
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JP4146514B2 (ja) 1995-07-06 2008-09-10 ノバルティス アクチエンゲゼルシャフト ピロロピリミジン類およびその製造方法
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SI0892789T2 (sl) 1996-04-12 2010-03-31 Warner Lambert Co Ireverzibilni inhibitorji tirozin kinaz
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
WO1998010121A1 (en) 1996-09-06 1998-03-12 Obducat Ab Method for anisotropic etching of structures in conducting materials
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
PT941227E (pt) 1996-11-18 2004-08-31 Biotechnolog Forschung Mbh Gbf Epothilona d sua preparacao e sua utilizacao como agente citostatico ou como agente de proteccao fitossanitaria
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
JP2002504540A (ja) 1998-02-25 2002-02-12 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ エポチロンの合成、その中間体およびそのアナログ
JP4516690B2 (ja) 1998-08-11 2010-08-04 ノバルティス アーゲー 血管形成阻害活性を有するイソキノリン誘導体
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
AU768220B2 (en) 1998-11-20 2003-12-04 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
JP4731016B2 (ja) 1998-12-22 2011-07-20 ジェネンテック， インコーポレイテッド 血管内皮細胞増殖因子アンタゴニストとその用途
ES2265929T3 (es) 1999-03-30 2007-03-01 Novartis Ag Derivados de ftalazina para el tratamiento de enfermedades inflamatorias.
US6703382B2 (en) 2000-08-16 2004-03-09 Georgetown University Medical Center Small molecule inhibitors targeted at Bcl-2
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
NZ529792A (en) 2001-05-30 2007-04-27 Univ Michigan Small molecule antagonists of Bcl-2 family proteins
US20030119894A1 (en) 2001-07-20 2003-06-26 Gemin X Biotechnologies Inc. Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
EP1778206A4 (en) * 2004-08-20 2009-08-05 Univ Michigan SMALL MOLECULAR INHIBITORS OF BCL-2 ANTI-APOPTOSIS FAMILY MEMBERS AND CORRESPONDING USES THEREOF
BRPI0514504A (pt) * 2004-08-20 2008-06-10 Univ Michigan pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas
CN101535280B (zh) 2006-11-15 2012-06-27 健泰科生物技术公司 芳基磺酰胺化合物
WO2011029842A1 (en) 2009-09-10 2011-03-17 Novartis Ag Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer
JP2015503516A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
US9126980B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
WO2013096060A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
KR20140107575A (ko) 2011-12-23 2014-09-04 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물

Also Published As

Publication number Publication date
AU2012355623A1 (en) 2014-07-17
EA201491264A1 (ru) 2014-11-28
KR20140104047A (ko) 2014-08-27
BR112014015322A8 (pt) 2017-06-13
MX2014007730A (es) 2015-01-12
CA2859869A1 (en) 2013-06-27
CN104125954A (zh) 2014-10-29
JP2015503518A (ja) 2015-02-02
US20140343093A1 (en) 2014-11-20
EP2794591A1 (en) 2014-10-29
US9126979B2 (en) 2015-09-08
WO2013096059A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
BR112014015322A2 (pt) compostos e composições para inibir a interação de bcl2 com parceiros de ligação
BR112014015339A2 (pt) compostos para inibição da interação de bcl2 com parceiros de ligação
BR112014015274A2 (pt) compostos e composições para inibição da interação de bcl2 com parceiros de ligação
BR112014015308A2 (pt) compostos para inibição da interação de bcl2 com contrapartes de ligação
BR112014015442A2 (pt) compostos e composições para inibir a interação de bcl2 com parceiros de ligação
BR112014007622A2 (pt) inibidores de flt3 cinase macrocíclicos
BRPI1006115A8 (pt) "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
BR112015014458A8 (pt) compostos derivados de manose, seus intermediários, composição, uso e processos de preparação
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
BR112015007083A2 (pt) inibidores de histona demetilases
BR112012012918A8 (pt) Agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
BRPI0916735B8 (pt) compostos moduladores de tgr5, composições farmacêuticas compreendendo os mesmos e seus usos
CR20180339A (es) INHIBIDORES DE PIRAZOLIL QUINAZOLINA CINASA (Divisional 2012-0576)
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
EA201201161A1 (ru) Пирролопиримидины в качестве ингибиторов cdk4/6
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
MX2020012695A (es) Compuestos de benceno substituidos con arilo o heteroarilo.
BR112013009093A2 (pt) dispersões sólidas contendo um agente indutor de apoptose
BR112012033402A2 (pt) moduladores de canais de íons conforme os compostos heterocíclicos fundidos
BR112013002914A2 (pt) promotores de apoptose de n-acilsulfonamida
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
BR112015023060A2 (pt) entidades químicas
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
BRPI0906444B8 (pt) compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired
B350 Update of information on the portal [chapter 15.35 patent gazette]